BTIG Reaffirms Buy Rating for Monopar Therapeutics (MNPR) Following Strong Phase 3 Wilson Disease Data

April 20, 2026 2:59 PM

BTIG analyst Jeet Mukherjee reiterated a Buy rating and $104.00 price target on Monopar Therapeutics (NASDAQ: MNPR)The analyst commented, "MNPR ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found